Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 14/20 | 0.86 |
| ▸ | TBXA2R | P21731 | 12/20 | 0.86 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.86 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.86 |
| ▸ | PTGIR | P43119 | 3/20 | 0.86 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.86 |
| ▸ | PTGFR | P43088 | 2/20 | 0.86 |
| ▸ | PDE4A | P27815 | 1/20 | 0.86 |
| ▸ | TSPO | P30536 | 1/20 | 0.86 |
| ▸ | DRD3 | P35462 | 1/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.86 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.86 |
| ▸ | PDE2A | O00408 | 7/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344139 | 1.00 | PTGDR (0.86) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Laropiprant SCHEMBL29612617 | 0.93 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Diastereomer 2 SCHEMBL32668949 | 0.93 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Diastereomer 2 SCHEMBL1044552 | 0.93 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Laropiprant SCHEMBL991107 | 0.93 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL991121 | 0.88 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL4548354 | 0.88 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL14472807 | 0.87 | PTGDR (0.85) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL19799336 | 0.85 | PTGDR (0.86) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL14318712 | 0.84 | PTGDR (0.65) | PTGDRTBXA2RPTGER2PTGER3PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INST NAT SANTE RECH MED (FR) | 2023-10-19 | — | — | US | disclosed |
| US-20180021302-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-01-25 | — | — | US | disclosed |
| US-9180114-B2 | Neurodegenerative diseases and methods of modeling | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-11-10 | — | — | US | disclosed |
| US-20100130574-A1 | NEURODEGENERATIVE DISEASES AND METHODS OF MODELING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-05-27 | — | — | US | disclosed |
| US-7317036-B2 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK FROSST CANADA & CO. (CA) | 2008-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130574-A1 | NEURODEGENERATIVE DISEASES AND METHODS OF MODELING | SMN1; SMN2, PTGDR2, PTGER1 | PTGDR 5/4885TBXA2R 106/4885PTGER2 12/4885 |
| US-20180021302-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR, PTGDR2, PTGIR | PTGDR 1/4885TBXA2R 10/4885PTGER2 9/4885 |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR2, PTGDR, PTGIR | PTGDR 2/4885TBXA2R 10/4885PTGER2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.